UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs

Oncotarget, 2010-11, Vol.1 (7), p.530-543

2010

Volltextzugriff (PDF)

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

The lancet oncology, 2019-09, Vol.20 (9), p.1306-1315

2019

Volltextzugriff (PDF)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000453

2020

Volltextzugriff (PDF)

PI3K pathway inhibitors: better not left alone

Current pharmaceutical design, 2013-02, Vol.19 (5), p.895-906

2013

Volltextzugriff (PDF)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

Oncoimmunology, 2021-01, Vol.10 (1), p.1908771-1908771

2021

Volltextzugriff (PDF)

Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities

Cancers, 2022-08, Vol.14 (17), p.4131

2022

Volltextzugriff (PDF)

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Clinical lung cancer, 2021-05, Vol.22 (3), p.e425-e430

2021

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3783-3790

2011

Volltextzugriff (PDF)

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution

Cancer reports, 2022-02, Vol.5 (2), p.e1465-n/a

2022

Volltextzugriff (PDF)

Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003156

2021

Volltextzugriff (PDF)

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3004-3004

2017

Volltextzugriff (PDF)

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

JTO clinical and research reports, 2022-11, Vol.3 (11), p.100400-100400, Article 100400

2022

Volltextzugriff (PDF)

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2

Recent patents on anti-cancer drug discovery, 2011-05, Vol.6 (2), p.210-236

2011

Volltextzugriff (PDF)

A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2603-2603

2022

Volltextzugriff (PDF)

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Clinical cancer research, 2020-09, Vol.26 (17), p.4454-4459

2020

Volltextzugriff (PDF)

Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2580-2580

2021

Volltextzugriff (PDF)

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy

Cancer cell, 2021-05, Vol.39 (5), p.592-593

2021

Volltextzugriff (PDF)

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

JAMA oncology, 2020-09, Vol.6 (9), p.1405

2020

Volltextzugriff (PDF)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2140-2150

2020

Volltextzugriff (PDF)

Phase I study of PTM-101 as neoadjuvant therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A trial in progress

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS775-TPS775

2023

Volltextzugriff (PDF)

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.181-193

2023

Volltextzugriff (PDF)

Abstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT253-CT253

2020

Volltextzugriff (PDF)

Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2020-08, Vol.152, p.103012, Article 103012

2020

Volltextzugriff (PDF)

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-01, Vol.28 (1), p.95-105

2022

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(158)

Publikationsform

Sprache

Englisch
(175)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Humans
(35)
Oncology
(35)
Female
(14)
Neoplasms - Drug Therapy
(13)
Adult
(12)
Aged
(12)
Cancer
(12)
Middle Aged
(12)
Tumors
(11)
Male
(10)
Patients
(9)
Animals
(8)
Immunotherapy
(8)
Aged, 80 And Over
(7)
Antineoplastic Agents - Pharmacology
(7)
Neoplasms - Pathology
(7)
Pharmacology & Pharmacy
(7)
Cancer Therapies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(80)
... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

PI3K pathway inhibitors: better not left alone

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution

Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2

A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Phase I study of PTM-101 as neoadjuvant therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A trial in progress

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Abstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Suchergebnisse filtern